Shunliang Gao

机构：Xiamen University, Hanzhong People's Hospital, Hanzhong Central Hospital, Shanghai Clinical Research Center, Pancreas Centre (Canada), First Affiliated Hospital Zhejiang University, Zhejiang University · ORCID：0000-0002-4330-7139

发表论文 102 篇 · 总被引 1671 次 · h-index 22

代表论文

• Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study (2024 · Signal Transduction and Targeted Therapy · 被引 39)
• Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial (2025 · Hepatology · 被引 28)
• 5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center (2025 · Cancer Letters · 被引 18)
• Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial (2025 · Cancer Cell · 被引 15)
• Clinical Significance and Risk Factors of Nonalcoholic Fatty Liver Diseases After Whipple Procedure (2024 · Journal of Surgical Research · 被引 5)
• Optimizing the Management Strategies of Delayed Postpancreaticoduodenectomy Hemorrhage (2024 · Annals of Surgery · 被引 5)